Literature DB >> 687511

Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.

J L Millar, B N Hudspith, T J McElwain, T A Phelps.   

Abstract

The lethal effect of high-dose melphalan in mice could be offset by pretreatment with cyclophosphamide, cytosine arabinoside or low-dose melphalan. The reason for improved survival is unclear. Althoug animals given high-dose melphalan died with symptoms of gut death, in only one instance, that with low-dose melphalan itself, did pretreatment protect the intestinal epithelium as measured by the microcolony assay. A small enhancement in the recovery of the haemopoietic tissue in pretreated animals was noted, although this on its own is unlikely to explain the phenomenon. Experiments in tumour-bearing mice showed that pretreatment with cyclophosphamide did not reduce the toxicity of melphalan to the Lewis lung carcinoma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 687511      PMCID: PMC2009698          DOI: 10.1038/bjc.1978.173

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Stem-cell survival and tumor control in the Lewis lung carcinoma.

Authors:  G G Steel; K Adams
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

2.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

3.  Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation.

Authors:  H R Withers; M M Elkind
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1970

4.  Kinetics of stem cell depletion and proliferation: effects of vinblastine and vincristine in normal and irradiated mice.

Authors:  W W Smith; S M Wilson; S S Fred
Journal:  J Natl Cancer Inst       Date:  1968-04       Impact factor: 13.506

5.  Enhanced post-irradiation recovery of the haemopoietic system in animals pretreated with a variety of cytotoxic agents.

Authors:  J L Millar; N M Blackett; B N Hudspith
Journal:  Cell Tissue Kinet       Date:  1978-09

6.  Combinations of cytotoxic agents that have less than expected toxicity on normal tissues in mice.

Authors:  J L Millar; T J McElwain
Journal:  Antibiot Chemother (1971)       Date:  1978

7.  Low-dose chemotherapy as a prelude to intensive treatment of spontaneous leukemia-lymphoma in AKR mice.

Authors:  W C Rose; A A Rimm; E C Saltzstein; R L Truitt; M M Bortin
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

8.  Sparing effect of cyclophosphamide (NSC-26271) pretreatment on animals lethally treated with gamma-irradiation.

Authors:  J L Millar; B N Hudspith
Journal:  Cancer Treat Rep       Date:  1976-04

9.  Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan.

Authors:  J L Millar; B N Hudspith; N M Blackett
Journal:  Br J Cancer       Date:  1975-08       Impact factor: 7.640

10.  Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.

Authors:  T C Stephens; J H Peacock
Journal:  Br J Cancer       Date:  1977-09       Impact factor: 7.640

View more
  15 in total

1.  Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.

Authors:  J Mansi; E Ellis; C Viner; J Mundy; T Smith; J Millar; S Milan; M Gore; D Cunningham
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  The effect of pretreatment with thio-TEPA and cytosine arabinoside on megakaryocytopoiesis in rats given a sublethal dose of thio-TEPA.

Authors:  G Tanum; A Sønstevold; A Engeset
Journal:  Blut       Date:  1987-01

3.  The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer.

Authors:  D J Perez; T J Powles; I E Smith; M D Vincent; S Ashley; C Gordon; J Gibb; S Clarke; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

Authors:  Jérôme Bouligand; Clémentine Richard; Dominique Valteau-Couanet; Cedric Orear; Lionel Mercier; Romain Kessari; Nicolas Simonnard; Fabienne Munier; Estelle Daudigeos-Dubus; Bassim Tou; Paule Opolon; Alain Deroussent; Angelo Paci; Gilles Vassal
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

Review 5.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.

Authors:  P J Selby; J L Millar; T A Phelps; M Y Gordon; R Wilkinson; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.

Authors:  A Zimber; K Perk; I Livnat
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.

Authors:  Simone S Riedel; Anja Mottok; Christian Brede; Carina A Bäuerlein; Ana-Laura Jordán Garrote; Miriam Ritz; Katharina Mattenheimer; Andreas Rosenwald; Hermann Einsele; Bjarne Bogen; Andreas Beilhack
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

9.  Epidermal growth factor (hEGF) has no effect on murine intestine epithelial damage and regeneration after melphalan.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

10.  Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.